一分钟看懂
这是一项关于非小细胞肺癌的II 期 / III 期研究，登记的药物或干预包括BMS-986504；Pembrolizumab；Placebo；Cisplatin；Carboplatin；Pemetrexed；Paclitaxel；Nab-paclitaxel，当前状态为招募中。登记地点显示中国合肥、北京、重庆、福州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BMS-986504；Pembrolizumab；Placebo；Cisplatin；Carboplatin；Pemetrexed；Paclitaxel；Nab-paclitaxel · II 期 / III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Local Institution - 0072 · 合肥
- Peking University People's Hospital · 北京
- Local Institution - 0049 · 北京
- Local Institution - 0286 · 北京
- Local Institution - 0621 · 北京
- Local Institution - 0108 · 重庆
- Fujian Cancer Hospital · 福州
- The First Affiliated hospital of Xiamen University · 厦门
- The First Affiliated Hospital, Sun Yat-sen University · 广州
- Guangdong Provincial People's Hospital · 广州
- Local Institution - 0061 · 广州
- Local Institution - 0281 · 深圳
- Guangxi Medical University Affiliated Cancer Hospital · 南宁
- Local Institution - 0408 · 贵阳
- Local Institution - 0353 · 石家庄
- Harbin Medical University Cancer Hospital · 哈尔滨
- Local Institution - 0107 · 郑州
- Local Institution - 0047 · 郑州
- Wuhan Union Hospital Cancer Center · 武汉
- Hubei Cancer Hospital · 武汉
- Local Institution - 0057 · 长沙
- Local Institution - 0387 · 长沙
- Hunan Cancer Hospital · 长沙
- Local Institution - 0352 · 南京
- Local Institution - 0279 · 南京
- Nanjing First Hospital · 南京
- The First affiliated hospital of Nanchang University (Xianghu campus) · 南昌
- Local Institution - 0075 · 长春
- Local Institution - 0284 · 沈阳
- Local Institution - 0104 · 沈阳
- Liaoning Cancer Hospital · 沈阳
- Local Institution - 0060 · 西安
- Local Institution - 0051 · 济南
- LinYi Cancer Hospital · 临沂
- Local Institution - 0068 · 青岛
- Shanghai Chest Hospital · 上海
- Zhongshan Hospital,Fudan University · 上海
- Local Institution - 0283 · 太原
- Sichuan Cancer hospital · 成都
- West China Hospital Sichuan University · 成都
- The first Affiliated Hospital, Zhejiang University School of Medicine · 杭州
- Local Institution - 0069 · 杭州
- Zhejiang Cancer Hospital · 杭州
公开的入选条件
- * Participants must have Metastatic (Stage IV or recurrent) non-small cell lung cancer (NSCLC) (as defined by the American Joint Committee on Cancer, Ninth Edition) with no prior systemic anti-cancer therapy for metastatic disease.
- * Participants must have histologically confirmed diagnosis of NSCLC and homozygous methylthioadenosine phosphorylase (MTAP) deletion or MTAP loss.
- * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- * Participants must have at least 1 measurable lesion as per RECIST v1.1.
- Exclusion Criteria
- * Nonsquamous participants must not have documented targetable oncogenic mutation or actionable genetic alterations (AGAs) for which there is a standard of care (SoC) available as first-line (1L) therapy.
- * Participants must not have symptomatic brain metastases or spinal cord compression.
- * Participants must not have any prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for metastatic non-small cell lung cancer (mNSCLC).
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07063745；登记信息更新于 2026-09-14。